Skip to main content
Fig. 3 | Acta Neuropathologica Communications

Fig. 3

From: Terminal complement pathway activation drives synaptic loss in Alzheimer’s disease models

Fig. 3

C7 therapeutic inhibits complement and modulates synapse loss in the hippocampus of AppNL−G−F mice. a Terminal complement complex (TCC) levels were significantly lower in anti-C7 mAb treated AppNL−G−F mice compared to irrelevant IgG controls at 6 months (n = 4–5). Groups were compared using an unpaired two-tailed t-test. b Representative confocal images of DiI labelled CA1 hippocampal dendritic segments from 6 month AppNL−G−F mice treated with anti-C7 mAb or IgG control. Scale bar 5 µm. DiI labelled dendritic spines were analysed from pre-fixed coronal brain slices. Spine densities were analysed from dendritic segments of at least 30 µm. c Dendrites were grouped based on proximity to thioflavin-S positive plaques. Dendritic segments within 50 µm of plaques were labelled peri-plaque (see Additional file 3: Fig. S3d), whereas dendrites with no adjacent plaques were labelled distal-plaque. Control IgG-treated but not anti-C7-treated mice showed significant reduction in peri-plaque compared to distal-plaque spine density. d Analysis of overall, stubby, mushroom and thin spine density in AppNL−G−F mice treated with control mAb. (C-D, n = 5 mice per group). Unpaired two-tailed t-test was used to compare spine densities between genotypes. Scale bar 5 µm. Error bars correspond to SEM. *P < 0.05, ** P < 0.01, ***P < 0.001

Back to article page